NCT07738614RecruitingPhase 1
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 28 Jul 2026
- Start date
- 31 Jul 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT07738614
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 56
- From 31 Jul 2026 to the primary completion date, Dec 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.
Lab values
- Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening
- A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)/deciliter (dL) or 7.0 millimoles (mmol)/liter (L), or
- Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol/mole (mol).
- Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, or GIP/GLP-1/glucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.
Other
- Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.
Who the study is looking for
- Have overweight or obesity, but are otherwise overtly healthy.
- Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive.
- Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lilly Centre for Clinical Pharmacology Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
| ICON Early Phase Services Coordinator of this site? Confirm its status | San Antonio | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.